218 patents
Page 7 of 11
Utility
JAK1 pathway inhibitors for the treatment of cytokine-related disorders
31 Aug 21
This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating cytokine-related diseases or disorders such as cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and CAR-T-cell-related encephalopathy syndrome (CRES).
Michael O'Neill Montgomery, Ahmad Naim, Susan Snodgrass
Filed: 14 Feb 19
Utility
Salts of TAM inhibitors
31 Aug 21
The present application provides salt forms of N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide and N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which are useful as inhibitors of TAM kinases, as well as processes and intermediates related thereto.
Zhongjiang Jia, Yongzhong Wu, Yongchun Pan, Jiacheng Zhou, Qun Li
Filed: 19 Mar 20
Utility
Crystalline solid forms of a BET inhibitor
17 Aug 21
The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.
Shili Chen, Zhongjiang Jia, Pingli Liu, Lei Qiao, Yongzhong Wu, Jiacheng Zhou, Qun Li
Filed: 24 Mar 20
Utility
Tricyclic heterocycles as BET protein inhibitors
17 Aug 21
The present invention relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
James D. Rodgers, Stacey Shepard, Haisheng Wang, Lixin Shao
Filed: 5 Sep 19
Utility
Heterocyclic compounds as PI3K-y inhibitors
17 Aug 21
Artem Shvartsbart, Stacey Shepard, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou, Andrew W. Buesking, Richard B. Sparks, Eddy W. Yue, Ravi Kumar Jalluri
Filed: 1 Oct 19
Utility
Salts and processes of preparing a PI3K inhibitor
10 Aug 21
The present application provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo [3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor phosphoinositide 3-kinase-delta (PI3Kδ), as well as a salt form and intermediates related thereto.
Lei Qiao, Lingkai Weng, David Meloni, Zhongjiang Jia, Jianji Wang, Jiacheng Zhou
Filed: 21 Jun 19
Utility
Heterocyclic derivatives as PI3K inhibitors
3 Aug 21
Stacey Shepard, Yanran Ai, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao, Artem Shvartsbart
Filed: 12 Nov 19
Utility
Salts of a Pim kinase inhibitor
20 Jul 21
The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.
Zhongjiang Jia, Qun Li
Filed: 21 May 19
Utility
Solid forms of an HPK1 inhibitor
20 Jul 21
The present invention relates to salt forms of the hematopoietic progenitor kinase 1 (HPK 1) inhibitors N-(2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-5-fluorophenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide and N-(2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-4-(4-cyanopyridin-3-yl)phenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide, including methods of preparation thereof, where the compounds are useful in the treatment of HPK1 mediated diseases such as cancer.
Zhongjiang Jia, William Frietze
Filed: 5 Aug 20
Utility
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
20 Jul 21
The present application provides dihydropyrido[2,3-d]pyrimidone inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Alexander Sokolsky, Liangxing Wu, Wenqing Yao
Filed: 10 Oct 19
Utility
1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
13 Jul 21
The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
Filed: 14 Aug 20
Utility
Heterocyclic compounds useful as Pim kinase inhibitors
6 Jul 21
The present application is concerned with heterocyclic compounds that inhibit the activity of Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancers and other diseases.
Oleg Vechorkin, Yun-Long Li, Alexander Sokolsky, Anlai Wang, Wenyu Zhu, Jincong Zhuo
Filed: 9 Sep 19
Utility
Substituted tricyclic compounds as FGFR inhibitors
6 Jul 21
The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
Liangxing Wu, Colin Zhang, Chunhong He, Liang Lu, Wenqing Yao
Filed: 7 Apr 20
Utility
Sustained release dosage forms for a JAK1 inhibitor
29 Jun 21
This invention relates to sustained release dosage forms comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and methods related thereto.
Krishnaswamy Yeleswaram, Bhavnish Parikh, Dilip P. Modi, Trupti Sheth
Filed: 17 Jan 20
Utility
Aminopyrazine derivatives as PI3K-γ inhibitors
29 Jun 21
Brent Douty, Yanran Ai, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Eddy W. Yue, Andrew W. Buesking
Filed: 1 Jul 19
Utility
Bicyclic heterocycles as FGFR4 inhibitors
25 May 21
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
Filed: 9 Jul 20
Utility
Pyrazolopyrimidine compounds and uses thereof
25 May 21
Oleg Vechorkin, Kai Liu, Jun Pan, Alexander Sokolsky, Hai Fen Ye, Qinda Ye, Wenqing Yao, Joshua Hummel
Filed: 3 Oct 19
Utility
Tricyclic heteroaryl compounds as STING activators
18 May 21
The present application provides tricyclic heteroaryl compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
Liangxing Wu, Yingda Ye, Wenqing Yao
Filed: 31 Jul 19
Utility
Bipyrazole derivatives as JAK inhibitors
11 May 21
Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
Filed: 29 Aug 19
Utility
Advanced gaming visualization system
13 Apr 21
A monocular unit permits visualization of image data received from an imaging device associated with a mobile computing device.
Ivan Arbouzov
Filed: 12 Jun 19